Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EASE SBS 2
NCT03905707Phase 3Completed
- Sponsor
- Zealand Pharma
- Start
- May 2019
- Primary completion
- Apr 2026
- Modality
- Peptides
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial of glepaglutide in short bowel syndrome (SBS) (2 arms), sponsored by Zealand Pharma. Primary endpoint: Adverse Events at 2 years. Started May 2019; status: completed.
02
Drugs
glepaglutide
03
Conditions
short bowel syndrome (SBS)
Beyond the preview
Go deeper on NCT03905707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03905707.